Table 2.
Clinical characteristics of patients with primary cervical lymphoma (N = 177)
| Clinical characteristics | Number (Percentile) |
|---|---|
| Age (Mean/Median, y) | 48.9 ± 15.8/49.0 (20–85) |
| Time of follow-up (Mean/Median, y) | 4.2/2.9 (0.08–20.50) |
| Maximum Tumor size (N = 106) | 6.9 ± 3.1 (0.5–18.0) |
| Elevated LDH (N = 28) | 16 (57.1%) |
| B symptoms | 12 (6.8%) |
| Ann Arbor Stage | |
| IE | 113 (63.8%) |
| IIE | 41 (23.2%) |
| IIIE | 4 (2.3%) |
| IVE | 19 (10.7%) |
| Pathological subtypes | |
| DLBCL | 113 (63.8%) |
| Follicular lymphoma | 14 (7.9%) |
| NK/T-cell lymphoma | 3 (1.7%) |
| Burkitt lymphoma | 1 (0.6%) |
| MALT lymphoma | 4 (2.3%) |
| B-cell NHL, unspecified | 14 (7.9%) |
| Other NHL, unspecified | 25 (14.1%) |
| Hodgkin lymphoma, unspecified | 3 (1.7%) |
| Cancer-directed surgery | 59 (33.3%) |
| Chemotherapy/Radiotherapy details | |
| No chemotherapy or radiotherapy | 12 (6.8%) |
| Chemotherapy alone | 77 (43.5%) |
| Radiotherapy alone | 31 (17.5%) |
| Radiotherapy + chemotherapy | 57 (32.2%) |
| With Rituximab | 39 (22.0%) |
| CHOP/CHOP-like chemotherapy (N = 134) | 104 (77.6%) |
| Clinical outcomes | |
| No evidence of disease | 143 (80.8%) |
| Alive with disease | 10 (5.7%) |
| Die of the disease | 19 (10.7%) |
| Die of the other disease | 5 (2.8%) |
Abbreviations: LDH lactate dehydrogenase, DLBCL diffuse large B-cell lymphoma, MALT Mucosa Associated Lymphoid Tissue, NHL Non-Hodgkin lymphoma, CHOP cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone